Public biopharmaceutical company valuations have taken a sharp turn into the red in the US during the past month, plunging the industry’s market for initial public offering into a drought. This trend reverses the flood of first-time offerings seen earlier this year when the number of drug developer IPOs surpassed the record set in 2020 before the end of the third quarter of 2021.
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
New Merck Debt Totals $8bn; ImmunoGen Raises $297.5m
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
More from Financing
More from Business
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?